Why don't we have insulin in

a pill? Because the stomach digests it

before it gets into the bloodstream. Pharmaceutical companies have long been working to overcome this

barrier, but until now, the little bit that made it into the bloodstream was

insufficient to make a difference. Until

now... maybe, hopefully! Clinical trial

results on a new insulin pill called Intesulin

have just been released showing that it is 60-70% as effective as injected

insulin. It lowered glucose levels

comparably, and kept those levels steady for patients throughout the day.

At the American Diabetes

Association conference this weekend, Coremed, Inc. announced new clinicalTake_a_pill_1


results on Intesulin in two "proof of principle" studies with Type 2 diabetics.

In both studies, Intesulin was compared to a placebo ("blank" pill) also to

Aspart analog (short-acting injected) insulin. Patients showed a significant decline

in C-peptide and rise in insulin levels, meaning their insulin resistance was

being suppressed. Intesulin has a first insulin peak at 30 minutes, compared to

Aspart, which peaks at 60 minutes. Overall, patients showed an average decline

of 30% in their daily average glucose levels. There wasn't a single incidence

of gastrointestinal irritations, adverse effects or hypoglycemia (low blood

sugar), the company reports.

Last year, Coremed, Inc.

also signed a joint venture partnership agreement with China-based Wanbang and

Fosun pharmas to develop its Alveair (TM) inhalable insulin,

which is also looking quite promising as an eventual competitor to Pfizer's


Disclaimer: Content created by the Diabetes Mine team. For more details click here.


This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.